Top of this page
Skip navigation, go straight to the content

Financials are on track for 2013 - more patients have access to UCB medicines

  • Posted by

    New figures published today show that our expectation for full-year and peak sales is on track, with total revenue of € 2.5bn for the first nine months of 2013 -so the financial outlook for the year was confirmed.

    Double-digit growth in net sales of our three core medicines continues to be a highlight, making up for the anticipated decline in sales from our established epilepsy therapy which is off-patent in the US and EU.

    We expect more patients will benefit from our core medicines in the years to come thanks to growth in emerging markets and Japan, as well as new indications in the US and EU for one of our key immunology products.

    Looking at the press release you will see that we hope to have more news to share as we are applying for an additional indication for our new epilepsy therapy and have several exciting new potential medicines in the pipeline.

    And the winner is…
    And the good news does not end there. On Thursday evening UCB won the award for best Annual Report from the Belgian Association of Financial Analysts (BVFA/ABAV).

    As regular readers will know, we have made a major effort to produce a more concise, more visual annual report which delivers the information you need in an easy-to-use format.

    I’d like to take this opportunity to thank all those who voted for UCB and to everyone who contributes to making our Annual Report the best it can be. Stay tuned for the Annual Report 2014, due end of February next year.

    For more information, please contact Antje Witte.

    Tags:
    Categories:
    Share:
  • Like